New cell therapy tested for tough blood cancers
NCT ID NCT07330895
Summary
This early study aims to find a safe dose of an experimental cell therapy called LV009 for adults whose CD19-positive blood cancers have returned or not responded to standard treatments. Researchers will give LV009 to up to 19 participants and closely monitor them for side effects for up to two years. The main goal is to understand how the body handles the treatment and what side effects might occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD19+ RELAPSE/REFRACTORY B-ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.